SEC Form 4 · accession 0001209191-16-107767
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua S Boger
Director
Period of report
Mar 9, 2016
Accepted (ET)
Mar 11, 2016 · 2:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 9, 2016 | M | 5,130 | $35.35 | A | 270,414 | D | |
| Common StockF2,F3 | Mar 9, 2016 | S | 2,830 | $84.94 | D | 267,584 | D | |
| Common StockF2,F4,F5 | Mar 9, 2016 | S | 2,300 | $85.84 | D | 265,284 | D | |
| Common Stock | holding | — | — | — | 13,286 | I | 401k | |
| Common StockF5 | holding | — | — | — | 122,700 | I | Common Stock Held In Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $35.35 | Mar 9, 2016 | M | 5,130 | D | — | Jul 19, 2016 | Common Stock | 5,130 | 87,220 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $84.94 (range $84.40 to $85.39).
- F4Open market sales reported on this line occurred at a weighted average price of $85.84 (range $85.40 to $86.35).
- F5Reflects a change in the form of ownership resulting from transfers of shares between trusts and Dr. Boger.
- F6Fully vested.